AKR1B1 and diabetic neuropathy: We previously reported the results of the 3-year Aldose Reductase Inhibitor—Diabetes Complications Trial (ADCT), which demonstrated the clinical efficacy of epalrestat, an ARI, in Japanese diabetic neuropathy patients with median motor nerve conduction velocity (MNCV) as the primary endpoint [10].